[SARS-CoV-2 Antibody Response to the Second COVID-19 Vaccination in Neuromuscular Disease Patients Under Immune Modulating Treatment]

Overview

Journal Nervenarzt

Specialty Neurology

Date 2022 Aug 23

PMID 35997783

Authors

S S Justus Hosseini

Anna Dudakova

Karsten Kummer

Jana Zschuntzsch

Affiliations

Soon will be listed here.

Abstract

Successful vaccination (adequate elevation of anti-spike protein antibodies) is attributed with sufficient protection against a severe course of coronavirus disease 2019 (COVID-19). For patients with chronic inflammatory diseases (CID) and immunosuppression the success of vaccination is an ongoing scientific discourse. Therefore, we evaluated the antibody titer against the S1 antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 2 weeks after complete immunization in patients with an underlying neuromuscular disease (NMD), who presented to our neurological day clinic and outpatient department for regular infusions of immunoglobulins. The data show that patients with chronic autoimmune NMD and simultaneous immunosuppressive or immune modulating treatment show an antibody response after vaccination with both mRNA and vector vaccines. In comparison to healthy subjects there is a comparable number of seroconversions due to the vaccination. A correlation between immunoglobulin dose and vaccination response could not be found; however, in contrast, there was a significant reduction of specific antibody synthesis, especially for the combination of mycophenolate mofetil (MMF) and prednisolone.

References

Hadjadj J, Planas D, Ouedrani A, Buffier S, Delage L, Nguyen Y . Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. 2022; 81(5):720-728. DOI: 10.1136/annrheumdis-2021-221508. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Stumpf J, Siepmann T, Lindner T, Karger C, Schwobel J, Anders L . Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021; 9:100178. PMC: 8299287. DOI: 10.1016/j.lanepe.2021.100178. View

Guimaraes P, Quirk D, Furtado R, Maia L, Saraiva J, Antunes M . Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021; 385(5):406-415. PMC: 8220898. DOI: 10.1056/NEJMoa2101643. View

Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K . Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021; 8:CD014963. PMC: 8406706. DOI: 10.1002/14651858.CD014963. View

Machado P, Lawson-Tovey S, Strangfeld A, Mateus E, Hyrich K, Gossec L . Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022; 81(5):695-709. DOI: 10.1136/annrheumdis-2021-221490. View

Simon D, Tascilar K, Kronke G, Kleyer A, Zaiss M, Heppt F . Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020; 11(1):3774. PMC: 7382482. DOI: 10.1038/s41467-020-17703-6. View

Jyssum I, Kared H, Tran T, Tveter A, Provan S, Sexton J . Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2022; 4(3):e177-e187. PMC: 8700278. DOI: 10.1016/S2665-9913(21)00394-5. View

Geisen U, Berner D, Tran F, Sumbul M, Vullriede L, Ciripoi M . Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021; 80(10):1306-1311. PMC: 8117443. DOI: 10.1136/annrheumdis-2021-220272. View

10.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

11.

Garcillan B, Salavert M, Regueiro J, Diaz-Castroverde S . Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines (Basel). 2022; 10(2). PMC: 8877652. DOI: 10.3390/vaccines10020297. View

12.

Simon D, Tascilar K, Fagni F, Kronke G, Kleyer A, Meder C . SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021; 80(10):1312-1316. PMC: 8103562. DOI: 10.1136/annrheumdis-2021-220461. View

13.

Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S . COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021; 3(6):e419-e426. PMC: 7993930. DOI: 10.1016/S2665-9913(21)00059-X. View

14.

. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View

15.

Deepak P, Kim W, Paley M, Yang M, Carvidi A, Demissie E . Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med. 2021; 174(11):1572-1585. PMC: 8407518. DOI: 10.7326/M21-1757. View

16.

Nimmerjahn F, Ravetch J . Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2007; 8(1):34-47. DOI: 10.1038/nri2206. View

17.

Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A . Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021; 385(7):661-662. PMC: 8262620. DOI: 10.1056/NEJMc2108861. View

18.

Dolscheid-Pommerich R, Bartok E, Renn M, Kummerer B, Schulte B, Schmithausen R . Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. J Med Virol. 2021; 94(1):388-392. PMC: 8426838. DOI: 10.1002/jmv.27287. View

19.

Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K . Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80(10):1317-1321. DOI: 10.1136/annrheumdis-2021-220503. View

20.

Lunemann J, Nimmerjahn F, Dalakas M . Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat Rev Neurol. 2015; 11(2):80-9. DOI: 10.1038/nrneurol.2014.253. View